Changeflow GovPing Healthcare & Life Sciences USPTO Patent Application: Thyroid Hormone Deliv...
Routine Notice Added Final

USPTO Patent Application: Thyroid Hormone Delivery Device

Favicon for changeflow.com USPTO Patent Applications - Medical Devices (A61M)
Published
Detected
Email

Summary

The USPTO has published a patent application (US20260083906A1) for a thyroid hormone delivery device. The application describes a subcutaneous implantable device with a microprocessor and precision pump for continuous thyroxine delivery, aiming to enhance patient compliance and metabolic control.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is a USPTO patent application (US20260083906A1) filed on September 21, 2024, for a novel thyroid hormone delivery device. The proposed device is designed for subcutaneous implantation and features a reservoir regulated by an embedded microprocessor and precision pump to ensure continuous and precisely dosed delivery of thyroxine at regular intervals.

While this is a patent application and not a regulation, it indicates potential future developments in medical devices for endocrine therapy. Companies involved in pharmaceutical manufacturing or medical device development, particularly those focused on drug delivery systems, should be aware of this technological advancement. There are no immediate compliance obligations or deadlines associated with this patent application.

Archived snapshot

Mar 26, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

Mechanisms for Thyroid Hormone Delivery

Application US20260083906A1 Kind: A1 Mar 26, 2026

Inventors

Brian Haney

Abstract

The present disclosure provides methods and a device for thyroxine delivery. This device is designed for subcutaneous implantation to ensure continuous delivery of thyroxine. It features a reservoir regulated by an embedded microprocessor with advanced signal software. The software triggers a precision pump to release a specific dose of thyroxine at regular intervals. This system enhances patient compliance and maintains optimal metabolic control.

CPC Classifications

A61M 5/14276 A61K 31/195 A61M 5/172

Filing Date

2024-09-21

Application No.

18892392

View original document →

Named provisions

Mechanisms for Thyroid Hormone Delivery

Get daily alerts for USPTO Patent Applications - Medical Devices (A61M)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
September 21st, 2024
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260083906A1

Who this affects

Applies to
Drug manufacturers Medical device makers Patients
Industry sector
3345 Medical Device Manufacturing 3254 Pharmaceutical Manufacturing
Activity scope
Drug Delivery
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Product Development
Topics
Medical Devices Drug Delivery

Get alerts for this source

We'll email you when USPTO Patent Applications - Medical Devices (A61M) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!